newsfilter
← Latest News
Business Wire·

Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

New data reveals Oncodetect's powerful prognostic performance in one of the largest TNBC MRD studies to date1 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today